primary studies published RCT Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Year: 2002 Date: 2002 Author: Ballmann M Source J Cyst Fibros. 2002 Mar;1(1):35-7. Study design (if review, criteria of inclusion for studies) Open cross-over pilot trial, with 2 treatment periods of 3 weeks, with a 3-week washout period. Participants Withdrawals were not discussed within the paper. 14 participants (mean age 13.3 years) with mild to moderate pulmonary involvement. Interventions Treatment consisted of 2 puffs salbutamol via a spacer prior to nebulization of 10 ml HS or 2.5 mg dornase alfa od. Outcome measures Changes from baseline for FEV1 (% predicted). Participants were assessed before and after each period.